# David R Sibley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2693905/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 101 papers | 3,059 citations | 218677 26 h-index | 168389 53 g-index |
| 105 all docs | 105 docs citations | 105 times ranked | 2794 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Molecular biology of dopamine receptors. Trends in Pharmacological Sciences, 1992, 13, 61-69. | 8.7 | 890 |
| 2 | Molecular Cloning of a Novel G Proteinâ€Coupled Receptor Related to the Opiate Receptor Family. Journal of Neurochemistry, 1995, 64, 34-40. | 3.9 | 216 |
| 3 | Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Molecular Psychiatry, 2021, 26, 6704-6722. | 7.9 | 139 |
| 4 | High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications, 2019, 10, 4627. | 12.8 | 128 |
| 5 | Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. Biochemical Pharmacology, 2012, 84, 882-890. | 4.4 | 116 |
| 6 | The Role of Phosphorylation in D1 Dopamine Receptor Desensitization. Journal of Biological Chemistry, 2004, 279, 7999-8010. | 3.4 | 94 |
| 7 | G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 Dopamine Receptor. Journal of Biological Chemistry, 2009, 284, 15038-15051. | 3.4 | 83 |
| 8 | Discovery and Characterization of a G Proteinâ€“Biased Agonist That Inhibits Î²-Arrestin Recruitment to the D2 Dopamine Receptor. Molecular Pharmacology, 2014, 86, 96-105. | 2.3 | 74 |
| 9 | Localization of D<sub>2</sub> dopamine receptors in vertebrate retinae with antiâ€peptide antibodies. Journal of Comparative Neurology, 1993, 331, 469-481. | 1.6 | 72 |
| 10 | [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. European Journal of Pharmacology, 1995, 272, R1-R3. | 3.5 | 70 |
| 11 | Zinc Allosterically Modulates Antagonist Binding to Cloned D<sub>1</sub> and D<sub>2</sub> Dopamine Receptors. Journal of Neurochemistry, 1997, 68, 1990-1997. | 3.9 | 68 |
| 12 | G Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation. Journal of Biological Chemistry, 2009, 284, 34103-34115. | 3.4 | 67 |
| 13 | N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor Selectivity. Journal of Medicinal Chemistry, 2011, 54, 3581-3594. | 6.4 | 64 |
| 14 | New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Molecular Psychiatry, 2020, 25, 2070-2085. | 7.9 | 55 |
| 15 | Identification of G Protein-Biased Agonists That Fail To Recruit Î²-Arrestin or Promote Internalization of the D1 Dopamine Receptor. ACS Chemical Neuroscience, 2015, 6, 681-692. | 3.5 | 53 |
| 16 | Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. , 1997, 26, 400-414. | | 52 |
| 17 | Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Translational Psychiatry, 2021, 11, 59. | 4.8 | 50 |
| 18 | Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. Cellular Signalling, 2018, 41, 75-81. | 3.6 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling. Neuropharmacology, 2008, 54, 1051-1061. | 4.1 | 45 |
| 20 | Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D<sub>3</sub> Receptor (D<sub>3</sub>R). Journal of Medicinal Chemistry, 2017, 60, 1478-1494. | 6.4 | 44 |
| 21 | D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse, 1996, 24, 156-164. | 1.2 | 39 |
| 22 | Identification of Positive Allosteric Modulators of the D<sub>1</sub> Dopamine Receptor That Act at Diverse Binding Sites. Molecular Pharmacology, 2018, 94, 1197-1209. | 2.3 | 35 |
| 23 | Pharmacological characterization of 2â€methoxyâ€Nâ€propylnorapomorphine's interactions with D<sub>2</sub> and D<sub>3</sub> dopamine receptors. Synapse, 2009, 63, 462-475. | 1.2 | 34 |
| 24 | Structural basis for Na<sup>+</sup>-sensitivity in dopamine D2 and D3 receptors. Chemical Communications, 2015, 51, 8618-8621. | 4.1 | 34 |
| 25 | Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Agonist Selectivity. Journal of Medicinal Chemistry, 2016, 59, 2973-2988. | 6.4 | 33 |
| 26 | Arrestin3 mediates D<sub>2</sub> dopamine receptor internalization. Synapse, 2009, 63, 621-624. | 1.2 | 32 |
| 27 | A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity. Science Signaling, 2020, 13, . | 3.6 | 31 |
| 28 | Agonist-induced morphologic decrease in cellular d1A dopamine receptor staining. Synapse, 1997, 27, 313-321. | 1.2 | 29 |
| 29 | D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 ï¿½ mesencephalon hybrid cell (MES-23.5) via distinct G proteins. Synapse, 1999, 31, 108-118. | 1.2 | 27 |
| 30 | Discovery, Optimization, and Characterization of Novel D<sub>2</sub> Dopamine Receptor Selective Antagonists. Journal of Medicinal Chemistry, 2014, 57, 3450-3463. | 6.4 | 27 |
| 31 | Measuring and Modeling the Spatiotemporal Profile of GABA at the Synapse. , 0, , 259-275. | | 24 |
| 32 | Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. European Neuropsychopharmacology, 2015, 25, 1448-1461. | 0.7 | 20 |
| 33 | A Mechanism Linking Two Known Vulnerability Factors for Alcohol Abuse: Heightened Alcohol Stimulation and Low Striatal Dopamine D2 Receptors. Cell Reports, 2019, 29, 1147-1163.e5. | 6.4 | 20 |
| 34 | Dopamine D<sub>4</sub> Receptor-Selective Compounds Reveal Structureâ€“Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry, 2019, 62, 3722-3740. | 6.4 | 20 |
| 35 | The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. PLoS Computational Biology, 2018, 14, e1005948. | 3.2 | 19 |
| 36 | The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Scientific Reports, 2020, 10, 2542. | 3.3 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The Dopamine D5 Receptor Is Involved in Working Memory. Frontiers in Pharmacology, 2017, 8, 666. | 3.5 | 15 |
| 38 | Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D<sub>3</sub> Dopamine Receptor Agonist. Journal of Medicinal Chemistry, 2020, 63, 5526-5567. | 6.4 | 15 |
| 39 | Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Molecular Psychiatry, 2022, 27, 4144-4156. | 7.9 | 15 |
| 40 | Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. Frontiers in Synaptic Neuroscience, 2018, 10, 2. | 2.5 | 14 |
| 41 | Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D<sub>2</sub>Dopamine Receptor. Molecular Pharmacology, 2021, 100, 372-387. | 2.3 | 14 |
| 42 | PNA-Based Multivalent Scaffolds Activate the Dopamine D<sub>2</sub> Receptor. ACS Medicinal Chemistry Letters, 2015, 6, 425-429. | 2.8 | 13 |
| 43 | Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D<sub>3</sub> Dopamine Receptor. ACS Chemical Neuroscience, 2020, 11, 3309-3320. | 3.5 | 13 |
| 44 | Dopamine D5 receptor-mediated decreases in mitochondrial reactive oxygen species production are cAMP and autophagy dependent. Hypertension Research, 2021, 44, 628-641. | 2.7 | 13 |
| 45 | Chemical Modification Strategies for Structure-Function Studies. , 0, , 125-141. | | 12 |
| 46 | Yeast as a Model System for Studying Glucose Transport. , 0, , 19-36. | | 11 |
| 47 | Families of Transporters and Their Classification. , 0, , 1-17. | | 10 |
| 48 | Ligand with Two Modes of Interaction with the Dopamine D<sub>2</sub> Receptorâ€“An Induced-Fit Mechanism of Insurmountable Antagonism. ACS Chemical Neuroscience, 2020, 11, 3130-3143. | 3.5 | 8 |
| 49 | Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential. Signal Transduction and Targeted Therapy, 2021, 6, 205. | 17.1 | 8 |
| 50 | Dopamine D1-like receptors regulate the Î±1A-adrenergic receptor in human renal proximal tubule cells and D1-like dopamine receptor knockout mice. American Journal of Physiology - Renal Physiology, 2014, 307, F1238-F1248. | 2.7 | 7 |
| 51 | A new era of rationally designed antipsychotics. Nature, 2018, 555, 170-172. | 27.8 | 7 |
| 52 | Development of pyrimidone D1 dopamine receptor positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2021, 31, 127696. | 2.2 | 6 |
| 53 | Sorting nexinâ€25, a novel member of the dopamine receptor signalplex, upâ€regulates D 1 and D 2 dopamine receptor expression in HEK293 cells. FASEB Journal, 2007, 21, A423. | 0.5 | 4 |
| 54 | Time will tell. Reply to â€œComments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.â€•by Chen et al.. Molecular Psychiatry, 2022, 27, 1863-1865. | 7.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Dopamine receptor interacting proteins: unraveling the receptor signalplex. FASEB Journal, 2008, 22, 726.3. | 0.5 | 1 |
| 56 | Characterization of the novel antiâ€cancer therapeutic ONC201 and related analogs as nonâ€competitive antagonists of the D 2 dopamine receptor. FASEB Journal, 2018, 32, 827.10. | 0.5 | 1 |
| 57 | Positive Allosteric Modulators of the D 1 Dopamine Receptor Act at Diverse Binding Sites. FASEB Journal, 2018, 32, 827.8. | 0.5 | 1 |
| 58 | Methanethiosulfonate Reagent Accessibility Studies, Cysteine-Scanning Mutagenesis, Protein Overexpression, and Functional Reconstitution: A Strategy for Studying the Structure/Function Relationships within the Mitochondrial Citrate Transport Protein. , 0, , 143-159. | | 0 |
| 59 | Amperometric Recording of Amphetamine-Induced Dopamine Efflux. , 0, , 191-201. | | 0 |
| 60 | Imaging Monoamine Transporters in the Brain. , 0, , 239-257. | | 0 |
| 61 | Peptide Mapping of Dopamine Transporter Ligand and Substrate Interaction Sites. , 0, , 161-177. | | 0 |
| 62 | Transgenic Mice in Monoamine Transporter Research. , 0, , 51-63. | | 0 |
| 63 | Studies of Glial Glutamate Transporters in Hippocampal Microcultures. , 0, , 217-238. | | 0 |
| 64 | Methods in Studying the Regulation and Trafficking of Transmembrane Transporters. , 0, , 111-123. | | 0 |
| 65 | Mass Spectrometry of Membrane Transport Proteins. , 0, , 179-189. | | 0 |
| 66 | Voltage Clamp and Fluorometric Techniques for Studying Glutamate Transporter Function. , 0, , 203-215. | | 0 |
| 67 | Searching for Novel Genetic Variation in Neurotransmitter Transporters. , 0, , 65-87. | | 0 |
| 68 | Neurotransmitter Transporters of Drosophila. , 0, , 37-50. | | 0 |
| 69 | Optimization of ML321: a D <sub>2</sub> dopamine receptorâ€selective antagonist for the treatment of neuropsychiatric disorders. FASEB Journal, 2021, 35, . | 0.5 | 0 |
| 70 | G proteinâ€coupled receptor kinase 2 can enhance Î²â€arrestin recruitment to the D <sub>2</sub> dopamine receptor in the absence of receptor phosphorylation. FASEB Journal, 2021, 35, . | 0.5 | 0 |
| 71 | Development of a dopaminergic neurodegeneration assay using laser cytometry of Caenorhabditis elegans models of Parkinson's disease. FASEB Journal, 2021, 35, . | 0.5 | 0 |
| 72 | D5 dopamine receptor regulation of Cu/Zn SOD expression and activity in D5 receptor deficient mice. FASEB Journal, 2006, 20, A309. | 0.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Reciprocal modulation of function between the D <sub>1</sub> and D <sub>2</sub> dopamine receptors and the Na <sup>+</sup> /K <sup>+</sup> â€ATPase, a novel member of the dopamine receptor signalplex. FASEB Journal, 2007, 21, A423. | 0.5 | 0 |
| 74 | Characterization of sorting nexinâ€25, a D 1 and D 2 dopamine receptor interacting protein that regulates receptor expression and trafficking in HEK293 cells. FASEB Journal, 2009, 23, 942.1. | 0.5 | 0 |
| 75 | Alterations in D2 dopamine receptor internalization in the presence of the Na+/K+â€ATPase. FASEB Journal, 2009, 23, 938.5. | 0.5 | 0 |
| 76 | Lipid rafts and membrane cholesterol are involved in regulating D2 dopamine receptor signaling. FASEB Journal, 2010, 24, 584.1. | 0.5 | 0 |
| 77 | Buspirone is a potent antagonist at D 3 and D 4 Dopamine Receptors and attenuates the reinforcing effects of cocaine in a primate model. FASEB Journal, 2012, 26, 661.4. | 0.5 | 0 |
| 78 | Investigation of the D 1 â€D 2 dopamine receptor heteromer reveals a complex signaling mechanism not limited to G q protein activation. FASEB Journal, 2013, 27, 881.1. | 0.5 | 0 |
| 79 | Identification of substituted benzazepines as functionally selective ligands of the D 1 dopamine receptor. FASEB Journal, 2013, 27, 655.3. | 0.5 | 0 |
| 80 | Identification of a novel, highly potent D3 dopamine receptorâ€selective agonist (662.8). FASEB Journal, 2014, 28, 662.8. | 0.5 | 0 |
| 81 | Identification of Structural Elements that Regulate Signaling Bias in D2-like Dopamine Receptors. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY20-1. | 0.0 | 0 |
| 82 | Identification of residues in the fifth transmembrane-spanning domain of the D2-like dopamine receptors that engender signaling bias. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-119. | 0.0 | 0 |
| 83 | Investigating the Interactions of GRK2 with a Gâ€protein Signalingâ€Biased D 2 Dopamine Receptor. FASEB Journal, 2018, 32, 827.13. | 0.5 | 0 |
| 84 | Discovery and characterization of a novel series of D2 dopamine receptorâ€selective antagonists though iterative chemistry of a BET bromodomain inhibitor. FASEB Journal, 2018, 32, 827.1. | 0.5 | 0 |
| 85 | Identification and Characterization of ML321: A Novel and Selective D 2 Dopamine Receptor Antagonist with Predicted Atypical Antipsychotic Properties. FASEB Journal, 2018, 32, 827.5. | 0.5 | 0 |
| 86 | Evidence for a Stereoselective Mechanism of Action for Nonâ€competitive Antagonism of the D3 Dopamine Receptor by Extendedâ€Length Bitopic Ligands. FASEB Journal, 2018, 32, 827.12. | 0.5 | 0 |
| 87 | In vivo Behavioral Characterization of ML417, a Novel D 3 Dopamine Receptorâ€selective Agonist. FASEB Journal, 2018, 32, 827.4. | 0.5 | 0 |
| 88 | Identification of Residues in the Fifth Transmembraneâ€Spanning Domain of the D2â€like Dopamine Receptors that Engender Signaling Bias. FASEB Journal, 2018, 32, 827.11. | 0.5 | 0 |
| 89 | Characterization of a Novel Series of D4 Dopamine Receptor Ligands Reveals Structureâ€Activity Relationships for Selective Partial Agonists. FASEB Journal, 2018, 32, 827.6. | 0.5 | 0 |
| 90 | Novel Dopamine D4 Receptorâ€Selective Compounds Reveal Structureâ€Activity Relationships that Engender Agonist Efficacy. FASEB Journal, 2019, 33, lb40. | 0.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | G proteinâ€coupled receptor kinases can enhance betaâ€arrestin recruitment to the D 2 dopamine receptor in the absence of receptor phosphorylation. FASEB Journal, 2019, 33, 502.1. | 0.5 | 0 |
| 92 | Identification of an agonist binding site motif that regulates biased signaling of GPCRs through altered conformations of intracellular loop 2. FASEB Journal, 2019, 33, 503.4. | 0.5 | 0 |
| 93 | Comparative Pharmacology and Structureâ€“Activity Relationships of D1 Dopamine Receptor Positive Allosteric Modulators. FASEB Journal, 2019, 33, 503.2. | 0.5 | 0 |
| 94 | Identification of a Novel Negative Allosteric Modulator of the D3 Dopamine Receptor. FASEB Journal, 2019, 33, 503.3. | 0.5 | 0 |
| 95 | Nonviral Gene Transfer Allows Up- and Down-Expression of the Brain Serotonin Transporter with Functional Consequences. , 0, , 89-110. | | 0 |
| 96 | Establishing an RNA interference (RNAi) screen for neuroprotection of dopaminergic neurons in Caenorhabditis elegans models of Parkinsonâ€™s disease. FASEB Journal, 2022, 36, . | 0.5 | 0 |
| 97 | Characterization and Chemical Optimization of the D2 Dopamine Receptorâ€Selective Antagonist, ML321, Identifies Lead Compounds for the Clinical Treatment of Neuropsychiatric Disorders. FASEB Journal, 2022, 36, . | 0.5 | 0 |
| 98 | Pharmacological actions of a novel and highly selective D3 dopamine receptor agonist, ML417, in a rodent model of Parkinsonâ€™s disease. FASEB Journal, 2022, 36, . | 0.5 | 0 |
| 99 | Structureâ€“Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site. FASEB Journal, 2022, 36, . | 0.5 | 0 |
| 100 | G proteinâ€coupled receptor kinases regulate &[beta]â€arrestin interactions with the D2 dopamine receptor in an isoformâ€specific manner and in the absence of direct receptor phosphorylation. FASEB Journal, 2022, 36, . | 0.5 | 0 |
| 101 | The show must go on. Reply to â€œDistinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et alâ€•by Insop Shim. Molecular Psychiatry, 0, , . | 7.9 | 0 |